PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Quebec Canada

Department of Urology Central Hospital of Bolzano Bolzano Italy

Department of Urology Groupe Hospitalier Pitié Salpêtrière Assistance Publique Hopitaux de Paris Faculty of Medicine Pierre et Marie Curie Institut Universitaire de Cancérologie GRC5 University Paris 6 Paris France; Department of Urology University Hospital Basel Basel Switzerland

Department of Urology Hospital Motol 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Medical University of Vienna Vienna General Hospital Vienna Austria

Department of Urology Medical University of Vienna Vienna General Hospital Vienna Austria; Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York New York

Department of Urology University of Texas Southwestern Medical Center Dallas Texas

Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York New York

Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York New York; Department of Urology Cochin Hospital Assistance Publique Hopitaux de Paris Paris Descartes University Paris France

Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York New York; Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Eur Urol. 2014 Aug;66(2):391. doi: 10.1016/j.eururo.2014.05.023. PubMed

References provided by Crossref.org